SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Oct 9, 2019
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Oct. 9, 2019 · CIK: 0001390478 · Accession: 0001300491-19-000007
AI Filing Summary & Sentiment
Reasoning
Letter
SELLAS Life Sciences Group, Inc.
15 West 38th St., 10th Floor
New York, New York 10018
October 9, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE:
SELLAS Life Sciences Group, Inc.
Registration Statement on Form S-3/A
Commission File No. 333- 233869
Acceleration Request
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Company”) hereby respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Friday, October 11, 2019, at 4:30 p.m. Eastern Time, or as soon as practicable thereafter.
The Company acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Any questions regarding this request should be addressed to Daniel A. Bagliebter, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 666 Third Avenue, New York, New York, 10017, telephone (212) 692-6856.
Very truly yours,
SELLAS Life Sciences Group, Inc.
Show Raw Text
CORRESP
1
filename1.htm
SELLAS Life Sciences Group, Inc.
15 West 38th St., 10th
Floor
New York, New York 10018
October 9, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE:
SELLAS Life Sciences Group, Inc.
Registration Statement on Form S-3/A
Commission File No. 333- 233869
Acceleration Request
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations
promulgated under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Company”) hereby
respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Friday,
October 11, 2019, at 4:30 p.m. Eastern Time, or as soon as practicable thereafter.
The Company acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The cooperation of the staff in meeting the timetable
described above is very much appreciated.
Any questions regarding this request should be addressed
to Daniel A. Bagliebter, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 666 Third Avenue, New York, New York, 10017,
telephone (212) 692-6856.
Very truly yours,
SELLAS Life Sciences Group, Inc.
/s/ Angelos M. Stergiou
By: Angelos M. Stergiou, M.D., Sc.D., h.c.
Its: President and Chief Executive Officer
cc: Cliff M. Silverman, Esq., Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.